U.S. markets closed

Clovis Oncology, Inc. (CLVS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.68+0.30 (+4.70%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close6.38
Open6.27
Bid6.65 x 4000
Ask6.71 x 3000
Day's Range6.13 - 7.10
52 Week Range3.62 - 11.63
Volume8,674,497
Avg. Volume5,197,645
Market Cap690.926M
Beta (5Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-5.01
Earnings DateFeb 23, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020
    Business Wire

    Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020

    Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2020. The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures.

  • Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug
    Zacks

    Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug

    Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.

  • Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial
    Business Wire

    Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial

    Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for FAP-2286, the lead compound in its peptide-targeted radionuclide therapy (PTRT) development program. Following clearance of the INDs by FDA, Clovis plans to initiate a Phase 1/2 clinical study of lutetium-177 labeled FAP-2286 (177Lu-FAP-2286) to determine the dose and tolerability of the FAP-targeting therapeutic agent (Phase 1), with expansion cohorts planned in multiple tumor types (Phase 2). FAP-2286 labelled with gallium-68 (68Ga-FAP-2286) will be utilized as a diagnostic to identify patients with fibroblast activation protein (FAP)-positive tumors appropriate for treatment with the therapeutic agent.